**<u>Lrig3 restricts the size of the colon stem cell compartment</u>**

Janelle G. Stevenson[1], Ryan Sayegh[2], Natalie Pedicino[3], Natalie A. Pellitier[4], Tim

Wheeler[1], Matthew E. Bechard[6], Won Jae Huh[5], Robert J. Coffey[6,7,8,9], Anne E. Zemper[1]

[1]Department of Biology, Institute of Molecular Biology, University of Oregon, Eugene, OR
97403

[2]Department of Molecular, Cellular, and Developmental Biology, University of Colorado,
Boulder, CO, 80309

[3]Department of Molecular, Cellular, and Developmental Biology, University of California
Santa Cruz, Santa Cruz, CA 95064

[4]Department of Medicine, Oregon Health and Science University, Portland, OR 97239

[5]Department of Pathology, Yale School of Medicine, New Haven, CT, USA

[6]Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232

[7]Department of Cell and Developmental Biology, Vanderbilt University Medical Center,
Nashville, TN 37232

[8]Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN 37232

[9]Department of Veterans Affairs Medical Center, Nashville, TN 37232

*Corresponding Author:
Anne E. Zemper, PhD
1229 University of Oregon
1318 Franklin Avenue
Room 273 Onyx Bridge
Eugene, OR 97403
Tel: 541-346-2403
Fax: 541-346-4854
E-mail: anniez@uoregon.edu
27

**Graphical Abstract**

**Abstract**

The cellular census of the colonic crypt is tightly regulated, yet the molecular

mechanisms that regulate this census are not fully understood. Lrig3, a transmembrane

protein, is expressed in colonic crypt epithelial cells, including the stem, progenitor, and

differentiated cell types. Mice missing Lrig3 have a disruption in their cellular census:

using a novel *Lrig3*[-/-] mouse we demonstrate that *Lrig3*[-/-] mice have more cells per crypt,

a greater mucosal area, and longer colons compared to wildtype mice, suggesting the

expression of Lrig3 is required for both the total number of epithelial cells in the mouse

colon, as well as colon length. In addition, we show *Lrig3*[-/-] mice have significantly more

stem, progenitor, and deep crypt secretory cells, yet harbor a normal complement of

enteroendocrine, Tuft, and absorptive cells. *Lrig3*[-/-] mice also have a concomitant

decrease in phosphorylated Extracellular signal-related kinases, indicating the loss of

Lrig3 leads to an expansion of the colonic stem cell compartment, in an Erk-dependent

manner. Our study describes the expression of Lrig3 within the colon, defines

perturbations in mice lacking *Lrig3,* and supports a role for Lrig3 in the establishment of

both colonic crypt structure and cellular census, defined as the epithelial cell type and

number in colon crypts.

**Introduction**

Precise spatiotemporal regulation of stem cell proliferation, differentiation, and

apoptosis are critical for proper regeneration of the gastrointestinal epithelium. In the

mouse colonic epithelium, the majority of cells are renewed every five days driven by

stem cell division at the base of the colonic crypt (10). In order to maintain crypt size and

epithelial cell number, the cellular census is tightly regulated by balancing the number of

stem, progenitor, and differentiated cells per crypt. We know that each of these cell types

are key for the absorptive and secretory jobs of the colon (13). Here, we evaluate how

the loss of Leucine-rich repeats and immunoglobulin-like domains 3 (*Lrig3*) affects crypt

cellular census and explore the impact of the loss of Lrig3 on these three critical cell types.

Lrig3 is a single-pass transmembrane protein and one of three members of the

Lrig protein family (22). Lrig family members generally regulate both receptor tyrosine and

serine/threonine kinases (22). To date, Lrig3 hasn't been as extensively studied as the

other Lrig family members, yet we know it is expressed across endo-, meso- and

ectodermal tissue types throughout embryonic development (8). Disruptions in Lrig3

affect proper neural crest formation in *Xenopus laevis* and result in incomplete formation

of the murine lateral semicircular canal (2, 30). Generally, mice, sheep and pig are smaller

if they have a loss-of-function in Lrig3 (1, 11, 15). Only recently have contributions to

primary literature uncovered mechanistic roles for Lrig3 in the progression of many cancer

cell types: cervical, hepatocellular, prostate, glioblastoma and colon (5, 6, 12, 17, 23, 24,

28).

While most adult vertebrates can survive and maintain some sort of

homeostasis with the loss of Lrig3, there are a number of defects that have been

described in knockout mice, including cardiac hypertrophy, misregulation of insulin levels

and the misorganization of neurons in the central nervous system (7, 11). In certain

tissues, Lrig3 works in concert with another family member, Lrig1 (7, 8). In the

gastrointestinal tract, Lrig1 is expressed on stem and progenitor cells in the small intestine

and colon and is functionally important for maintaining homeostasis. The loss of Lrig1

results in aberrant growth factor signaling and tumor formation (18, 25). From publicly-

available expression databases, we know Lrig3 is also highly expressed in the

gastrointestinal tract (32) and Lrig3 protein is predicted to have striking homology to Lrig1

(22). These reasons led us to hypothesize that Lrig3 is important for development and

homeostasis of the mouse colon. The goal of our study was to understand the impact of

the loss of Lrig3 on colon biology. Through transcript and protein expression analysis, we

show that Lrig3 is present throughout the colonic crypt epithelium, and we describe

multiple colon morphological and cellular defects in *Lrig3*$^{-/-}$ mice. Our study describes the

expression of Lrig3 within the colon, defines perturbations in mice lacking *Lrig3,* and

supports a role for Lrig3 in the establishment of both colonic crypt structure and cellular

census, defined as the epithelial cell type and number in colon crypts.

**Results**

**Lrig3 expression in colonic crypts**

Our first step was to define Lrig3 expression in the colonic crypts by assessing *Lrig3*

transcript and Lrig3 protein expression via *in situ* hybridization, immunofluorescence, and

western blot analysis, respectively. We generated an *Lrig3* knockout mouse (*Lrig3$^{-/-}$*, Fig.

1*A* and Supplemental Fig. S1) to both serve as a control for these analyses and to

evaluate the impact of the loss of *Lrig3*. Comparing wildtype (WT) tissue to *Lrig3$^{-/-}$* tissue,

we observed *Lrig3* transcript expression in all colonic epithelial cells and this expression

was lost in the *Lrig3$^{-/-}$* mice (Fig. 1*B-E*). Further, Lrig3 protein is expressed in the majority

of epithelial cells; this was confirmed by immunofluorescence and western blot analyses.

Lrig3 protein was absent in *Lrig3$^{-/-}$* mice (Fig. 1*F-J*). These results define, for the first time,

Lrig3 expression in the mouse colonic crypt.

**$Lrig3^{-/-}$ mice have morphological and epithelial defects**

As our initial results demonstrate that Lrig3 is highly expressed throughout the colonic

crypt, we posited there may be epithelial disruption to the crypts in mice lacking *Lrig3*.

Indeed, initial survey of the colonic tissues indicated morphological differences, as well

as epithelial cellular census differences between WT and *Lrig3$^{-/-}$* mice. To examine this

directly, we first assessed colon lengths, and found that adult *Lrig3$^{-/-}$* mice have

significantly longer colons than WT mice at 6-10 weeks of age (p<0.05, Fig. 2*A*). We

hypothesized that along with the observed increase in colon length there may be

alterations at the cellular level. We examined this by measuring total mucosal area of WT

and *Lrig3$^{-/-}$* mice using hematoxylin and eosin stained, paraffin-embedded tissue sections

and found that *Lrig3$^{-/-}$* mice have a significantly larger mucosal area (p<0.01, Fig. 2*B-D*),

per tissue section. The larger mucosal area in *Lrig3$^{-/-}$* mice could be for several reasons,

but we prioritized the investigation of two obvious hypotheses: 1) the epithelial cells within

*Lrig3⁻ᐟ⁻* mice are larger or 2) there are more cells present in the crypts of *Lrig3⁻ᐟ⁻* mice.

After an extensive examination of the colon sections from both sets of mice, we

determined there was no obvious difference in cellular size between the cohorts (data not

shown), ruling out that hypothesis. To investigate our second hypothesis, we quantified

the number of epithelial nuclei per crypt, across both cohorts, and found that *Lrig3⁻ᐟ⁻* mice

have more cells per colonic crypt than the WT mice (p<0.05, Fig. 2*E*). While there could

be many reasons for a greater number of cells, we first examined proliferation in the crypt

of *Lrig3⁻ᐟ⁻* mice compared to WT mice by quantifying the expression of Ki67, a proliferative

marker, in the epithelial cells. Surprisingly, we found no significant difference in the

number of proliferating epithelial cells in the colonic crypts of *Lrig3⁻ᐟ⁻* mice at 6-10 weeks

of age, compared to WT mice of the same age (Fig. 2*F-J*). From these analyses, we

conclude that *Lrig3⁻ᐟ⁻* mice have a greater number of cells per crypt, but these cells are

not undergoing aberrant proliferation.

**Colon crypt stem compartments are expanded in *Lrig3⁻ᐟ⁻* mice**

As epithelial cell number expansion is a hallmark of *Lrig3⁻ᐟ⁻* crypts, we wondered if this

increased cell number was attributed to a particular region of the crypt. As there are many

cell types present, we first assessed the stem and progenitor cells in the crypt-base by

examining *Lgr5* expression, as this is indicative of the presence of long-lived proliferative

stem cells in the base of the colonic crypt (4). First, we performed RNA Scope *in situ*

hybridization for *Lgr5* expression and identified significantly more *Lgr5+* cells in the

colonic crypts of *Lrig3⁻ᐟ⁻* mice (Fig. 3*A-D*). In addition, some cells seemed to harbor

qualitatively more *Lgr5* than others, even in the WT tissue, consistent with previous

analyses of stem and progenitor markers in the gut (10). To more carefully examine this

observation, we devised a quantification scheme for looking at *Lgr5* transcript expression

levels in each cell. We binned them according to low- (<6 puncta per cell), mid- (6-14

puncta per cell), and high (15≤ puncta per cell) ranges (Fig. 3*E*). We quantified the puncta

in *Lrig3*-/- and WT cells and while we observed no difference in the number of *Lgr5* low-

expressing cells, there were significantly more mid- and high-expressing cells in *Lrig3*-/-

mice (p<0.001, Fig. 3*F*). The other cell type present in the stem cell region of the crypt is

defined by the expression of the Reg4 protein. As Reg4+ cells act as support cells for

Lgr5+ cells (20), we reasoned that we may also observe a parallel increase in Reg4+

cells, in *Lrig3*-/- mice. To determine this, we quantified the number of Reg4+ cells and

found significantly more Reg4+ cells in the base of the crypt (p<0.0001, Fig. 3*G-K*). Reg4

is also expressed by secretory cells near the top of the crypt, thus we quantified the

number of Reg4+ cells in the upper half of the crypt and determined there is no change

in the number of these cells between *Lrig3*-/- and WT mice (Fig. 3*L*). Finally, we examined

the number of Vil-1+ (absorptive), Dclk1+ (Tuft), and ChgA+ (enteroendocrine) cells,

which correspond to three additional differentiated cell types found in the upper portion of

the crypts. Qualitatively, we found no obvious difference in Vil-1 expression, when

comparing approximately 50 images per genotype. Quantitatively, we found no difference

in Dclk1+ and ChgA+ cells when comparing *Lrig3*-/- and WT mice (Supplemental Fig. S2).

Collectively, our results demonstrate the increased cell number we observe in *Lrig3*-/- mice

is restricted to stem and support cells in the crypt base.

**_Lrig3_-/- mice have increased Lrig1 and decreased in pErk**

As the stem cell niche is expanded in *Lrig3*-/- mice, we next examined if there was any

change in expression of Lrig1, which is an Lrig3 family member, and widely expressed in

intestinal stem and progenitor cells(18). While Lrig1 is normally restricted to the crypt-

base, we found that Lrig3-/- mice have more Lrig1+ cells in the mid- and upper-crypt (Fig.

4A-D). We quantified the number of Lrig1+ cells per crypt and found significantly more

Lrig1+ cells in Lrig3-/- mice compared to WT mice (p<0.0001, Fig. 4E). We also quantified

Lrig1 expression in the crypts via western blot analysis and confirmed the increase in

Lrig1 we detected in Lrig3-/- mice (Fig. 4F). As loss of Lrig1 results in changes to growth

factor receptor signaling (18, 26), we next assessed if the over-expression of Lrig1 seen

in Lrig3-/- mice resulted in cell signaling changes in the crypts. We prioritized analysis of

total and activated Epidermal growth factor receptor (Egfr and pEgfr, respectively), as

these receptors are modulated based on Lrig1 expression (18). We also examined

extracellular signal-related kinase (Erk) expression, as this is a transcriptional activator of

proliferation and differentiation, and promoter of stemness in both the small intestine and

colon (16). We observed no obvious differences in the protein expression of total Egfr

(Fig. 4G-H, K), activated Egfr or total Erk (Fig. 4I-K); however, we consistently observed

decreased expression of phosphorylated Erk (pErk) in the Lrig3-/- colonic crypts by

western blot analysis (Fig. 4K). These results indicate this common downstream mediator

of mitogen activated kinase signaling is changed in mice lacking Lrig3. Taken together,

we observe that Lrig3 is required for proper Lrig1 expression and appropriate Erk

activation.

**Discussion**

Using our novel Lrig3-/- mouse, we demonstrate that Lrig3-/- mice have more cells per

crypt, a greater mucosal area, and longer colons compared to wildtype mice. This

suggests the expression of Lrig3 is required for both the total number of epithelial cells in

the mouse colon, as well as establishment of colon length. Further, we show *Lrig3*[-/-] mice

have an Erk-associated expansion of the colonic stem cell compartment, as they harbor

significantly more stem, progenitor, and deep crypt secretory cells.

Our research defines the expression domain of Lrig3, in the colon for the first time,

as a novel marker of all colonic epithelial cells. The most well-studied Lrig family member,

Lrig1 (18), is a homologue of Lrig3 with redundant expression patterns in some tissues

(7, 8). In the colon, Lrig1 expression is distinct from that of Lrig3, as it is restricted to the

crypt-base (18, 26). As their expression patterns are distinct in the gastrointestinal tract,

it is likely that Lrig1 and Lrig3 also have unique molecular functions. *In vitro*, we know that

Lrig3 stabilizes the ErbB receptors, whereas Lrig1 promotes ErbB receptor degradation

(18). It is less clear if Lrig3 also promotes stabilization of ErbB receptors *in vivo*; this

observation may be tissue-dependent (3). As with Lrig1, Lrig3 has been evaluated across

many tissue types; and has a significant impact on growth factor receptor pathways. We

show that one common mediator of ErbB and Ras signaling pathways, Erk, is

dysregulated in *Lrig3*[-/-] mice. Through our examination of the ErbB family member, Egfr,

we did not observe any changes to expression or activation of this powerful growth factor

receptor in *Lrig3*[-/-] mice; the impact of Lrig3 loss on other growth cell signaling pathways

represents an important area of future research. Lrig3 also has been shown to regulate

fibroblast growth factor (FGF) receptors which results in changes to neural crest formation

in frog (30) and vascular endothelial growth factor (VEGF) receptors are modulated by

Lrig3 in glioma (17, 31). Both FGF and VEGF pathways are important for the development

and maintenance of the colonic epithelium (9, 21), but it is unknown if Lrig3 modulates

these pathways in this context. This represents an important area of future research.

The question of how Lrig3 is regulated may be equally as important as the question

as to what Lrig3 is regulating. Notably, *Lrig3* expression is directly modulated by miRNA-

196a, a microRNA that is upregulated in gastric, colon, breast and pancreatic cancer and

promotes tumorigenesis. In cervical cancer cells, miRNA-196a targets Lrig3 (19) and

improves cell viability. Lrig3 is also regulated at the post-transcriptional level, as there are

reports of a circular form of Lrig3 *(circRNA Lrig3)* that is highly expressed in human

hepatocellular carcinoma (HCC). Detection of blood plasma *circ-Lrig3* is a highly sensitive

and specific diagnostic indicator for HCC (23). Mechanistically, downregulation of

*circRNA Lrig3* represses both the MAPK/ERK and Smad pathways to prevent the

progression of HCC and the loss of *circRNA Lrig3* suppresses proliferation, invasion of

HCC cells *in vitro* and blocks tumor growth of HCC *in vivo* (12, 24). One recent report

gives us a glimpse of the potential role in advanced colon cancer. Using human colon

cancer cell lines, Zang and colleagues were able to show that Lrig3 represses metastasis-

associated cell motility by inhibiting slug via inactivating ERK signaling (29). While the

data on Lrig3 expression in solid tumors is expanding rapidly (5, 6, 12, 17, 23, 24, 29),

the role of Lrig3 in the gastrointestinal tract at the genome, transcriptional and protein

level is largely unknown and represents a valuable avenue for future research for both

normal and cancerous colon tissue.

In terms of the requirement for Lrig3 in colon development and homeostasis, we

have two key observations. The first is that *Lrig3⁻/⁻* mice are born physically smaller and

weigh less than their WT counterparts (11), yet we also consistently observe these mice

to have significantly longer colons at adulthood. While there has been a great deal of

research defining the molecular requirements for small intestinal morphogenesis, and to

some extent, for the colon (9, 13), our results clearly signify the importance of studying

Lrig3 and its role in colon development. While it is beyond the scope of this paper, a clear

next step to understanding how *Lrig3* impacts colon development is to take an *in vivo,*

inducible loss-of-function approach for Lrig3, using a timecourse strategy to define the

impact of loss of Lrig3 on birth weight and colon length.

Perhaps the most striking observation from our examination of *Lrig3*[-/-] mice is the

greater number of cells per crypt despite no significant change to proliferation, resulting

in *Lrig3*[-/-] mice having an expanded pool of stem and support cells in the crypt-base. While

colonic epithelial self-renewal has been extensively researched (10) the majority of this

research has been in adult mice, and generally has been assessed during regenerative

phases after tissue injury (27). From these studies, we know the key signaling pathways

that promote stem cell self-renewal and daughter cell differentiation (10). Cellular census

(epithelial cell type and number) is generally consistent from crypt-to-crypt in the distal

colon of both mice and humans. Unfortunately, there is a paucity of research examining

the molecular factors that regulate the number of colon cells and how the crypts arrive at

a homeostatic census (and thus a consistent crypt size) in adulthood. Our data clearly

demonstrate the requirement for proper Lrig3 expression to yield appropriate crypt cellular

census. Despite the increase in cell number per crypt in *Lrig3*[-/-] mice, we do not observe

an increase in all epithelial cell types. Indeed, we observe a specific increase in the

number of cells in the stem cell compartment at the crypt-base, suggesting that *Lrig3* is

critical for establishing the size of the stem cell compartment during development. In

future experiments, it will be important to test this hypothesis directly, either by

overexpression of Lrig3 or through forced, wide-spread regeneration of colon crypts in

*Lrig3*$^{-/-}$ mice. In the latter example, induction of acute injury to the adult *Lrig3*$^{-/-}$ colon to

spur crypt renewal will be instructive in understanding how *Lrig3*$^{-/-}$ mice arrive at this

aberrant state of homeostasis. Taken together, our results signify the importance of

studying Lrig3 and its role in cellular census and colon development.

**<u>Experimental Procedures</u>**

**Generating *Lrig3*$^{-/-}$ mice** – The *129 Lrig3* BAC clone (bMQ-129G9) was obtained from

Sanger Institute. The *Lrig3* targeting construct which disrupts exons 4-12 of the Lrig3

locus was generated by BAC recombineering (14). The gene disruption strategy, null

allele sequence and location of PCR primers is presented in Supplemental Figure 1. PCR

primer sequences are listed in Supplemental Table 1. ES cell electroporation and

subsequent blastocyst injections were performed by the Transgenic Mouse/ES Cell

Shared Resource at Vanderbilt University.

**Mice** – C57BL/6 and *Lrig3*$^{-/-}$ mice were housed in a specific pathogen-free environment

under controlled light cycle conditions, fed standard rodent lab chow, and provided water

*ad libitum*. All procedures were approved and performed in accordance with the University

of Oregon Institutional Animal Care and Use Committee. All mice were used at 6-10

weeks and mouse sex was mixed male to female at a roughly 50% ratio of each. All mice

were sacrificed by cervical dislocation. At time of sacrifice, colons were removed, flushed

with ice cold PBS and immediately measured using a ruler to obtain colon length, and

then bifurcated.

**Tissue Preparation for Staining** – Tissue for paraffin and frozen block preparation were

pinned onto a wax surface, fixed using 4% paraformaldehyde (PFA) for one hour (tissue

imaged in Fig1*G-J* were fixed in 4% PFA overnight), on a shaker at room temperature.

They were then washed three times (five minutes each) in PBS. For frozen blocks, tissue

was submerged 30% sucrose in PBS overnight at 4°C and embedded in optimal tissue

compound (OCT) for subsequent sectioning. For paraffin blocks, tissue was incubated in

70% ethanol and dehydrated in increasing alcohol baths and embedded in paraffin wax.

All slides were sectioned at 7μm, (unless stated otherwise), and stained according to

procedures below.

**Colonic Crypt Protein Isolation** – Bifurcated colons were cut into ~ 1cm pieces and

incubated in ice cold 2mM EDTA and 0.5mM DTT PBS buffer, washed in PBS, and

incubated 2mM EDTA buffer at 37°C. Tissue underwent vigorous lateral shaking to

release crypts from submucosa, suspension was decanted, and shaking was repeated

three times. The presence of single crypts is verified under a compound microscope and

residual submucosal tissue is removed. The final collection of crypt suspensions was

centrifuged at 500xg, cell pellet was then resuspended in Pierce RIPA buffer

(ThermoFisher) with protease (½ tablet, Pierce Protease Inhibitor Mini tablets, EDTA-

free, ThermoFisher) and phosphatase inhibitor (½ tablet PhosSTOP EASYpack, Roche),

homogenized using an 18-gauge needle, and centrifuged at maximum speed. The

supernatant was removed, and protein concentration determined using Pierce BCA kit

(ThermoFisher).

**Morphometric Analysis** – Mucosal area and nuclei per crypt were quantified using

paraffin embedded tissue and stained with Hematoxylin and Eosin (VWR). Images and

measurements were obtained on a Nikon Eclipse/Ds-Ri2. To quantify the mucosal area

we measured 10 images per animal (n=4 mice per genotype) using the Nikon NIS-

Elements measurement tool. We measured the area of colonic epithelium by drawing

lines across the basement membrane of the epithelium, along the sides, and across the

luminal edge. To quantify the nuclei per crypt we used Hematoxylin and Eosin-stained

paraffin slides and counted total nuclei per crypt in 10 images per animal (n=4 mice per

genotype).

**Antibodies and Staining Procedure** – Frozen tissue slides were washed in PBS three

times (three minutes each), blocked in 1% bovine serum albumin (BSA) and 0.03% Triton

X-100 suspended in PBS for 1 hour. Antibodies were diluted in this blocking buffer at

concentrations listed in Supplemental Table 1, applied to the sections and sections were

incubated overnight at 4°C. Slides were then washed in PBS three times (three minute

each) and incubated with secondary antibodies at 1:500 in the same blocking buffer as

above, for one hour at room temperature. Lastly, slides were washed in PBS for three

minutes, then washed in PBS plus DAPI (1:10,000) for five minutes, and finally washed

in PBS for three minutes. Slides were mounted using an n-propyl gallate/glycerol solution.

Paraffin slides underwent conventional deparaffinization in xylenes and rehydration via

ethanol washes and water, followed by antigen retrieval in a 1x Citrate buffer

(ThermoFisher) in a pressure cooker for one hour. Antibody catalog information and

concentrations used are listed in Supplemental Table 2.

**Western Blot** – Protein was diluted in a Laemmli buffer with 5% β-mercaptoethanol and

boiled at 95°C for five minutes. 25µg of protein was loaded per lane into an SDS-PAGE

gel (Bio-Rad Mini-Protean pre-cast gels 4-20%) and gels were run at 160V for

approximately 90 minutes. Protein was transferred from the gel to a PVDF membrane

overnight at 55V at 4°C. Membranes were blocked in either 5% dry milk or 5% BSA in

PBS for one hour and incubated in primary antibody overnight at 4°C. Membranes are

then incubated in HRP-conjugated secondary antibodies at room temperature for one

hour. ECL reagent (GE Healthcare) was then applied and subsequent images were

captured on a LI-COR Odyssey Fc Imaging System. For quantification of protein levels

of target proteins, β-tubulin was used as a normalization control (n=3 mice per genotype).

***In Situ* hybridization** – *In situ* hybridization was conducted using RNAscope Multiplex

Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics #323110) according to

manufacturer protocols for fixed, frozen tissue sample preparation protocol (ACD TN

320535 Rev A, 323100-USM). Briefly, 15um frozen sections were washed briefly in PBS,

boiled for 5 minutes in 1x Target Retrieval buffer, followed by two brief washes in ddH$_2$O

and one in 95% EtOH. Slides were dried then dammed with an ImmEdge hydrophobic

barrier pen, then incubated with Protease III for 15 minutes at 40°C. Slides were washed

briefly in ddH$_2$O, then incubated at 40°C in sequence with Probe-Mm-Lgr5 (312171) or or

Mm-Lrig3 probe (310541) (2hr), AMP 1 (30 min), AMP 2 (30 min), AMP 3 (15 min), HRP-

C1 (15 min), Opal-570 TSA (30 min, 1:1000), with two two-minute washes with 1x Wash

Buffer between hybridization steps. Slides were counterstained with DAPI and mounted

with N-propyl gallate mounting medium.

**Fluorescence microscopy: image acquisition and analysis** – Images for

quantification of all immunofluorescent and RNAscope images were obtained using a

Nikon Eclipse/Ds-Ri2 and NIS Elements software tools. Lrig3 antibody was visualized

using confocal microscopy on a Zeiss LSM-880 system. Images were false-colored in

Adobe Photoshop. All image analysis and quantification was performed in a double-blind

fashion and statistical comparisons were analyzed using GraphPad Prism software.

Quantification of all images (total "n" and counting metrics) are designated in each figure

legend, however there were two sets of images analyzed with different criteria and we

explain them here. For the quantification of *Lgr5* expression, images were acquired and

binned according to low- (<6 puncta per cell), mid- (6-14 puncta per cell), and high (15<

puncta per cell) expression levels. Example images are shown in Fig. 3*E*. For Reg4

quantification, we separated each colonic crypt in half (upper and lower regions) and

counted the positive cells in each region. Example images are shown in Fig. *H* and *J*, with

the dotted white line separating upper from lower.

**Figure Legends**

**Figure 1. Lrig3 expression in the colonic epithelium**. A. Schematic depicting knockout

of exons 4-12 in the *Lrig3*[-/-] mice, compared to WT mice. Blue antibody drawing indicates

where Lrig3 antibody (panels F, G-J) antigen is located. Blue line indicates where *Lrig3*

RNA SCOPE probe (panels B-E) is located. B-C. Representative epifluorescence RNA

SCOPE images of colonic tissue cross sections indicating *Lrig3* transcripts (green) are

located largely within the colonic epithelial compartment in wildtype mice. In *Lrig3*[-/-] mice

(D-E), RNA SCOPE signal (green) is lost (n=3 mice/genotype, 16 images/mouse). F.

Western blot comparing Lrig3 antibody reactivity in wildtype and *Lrig3*[-/-] colonic epithelial

cell isolation lysates (n=3). G-J. Representative images from a single confocal slice

illustrating Lrig3 antibody reactivity with wildtype (G-H) colonic tissue (green) cross-

sections (n=3 mice/genotype, 10 images/mouse). Background fluorescence observed in

Lrig3[-/-] (I-J). Scale bars indicate 50um. Nuclei in B-E and G-J are depicted in magenta. B,

D, G and H are single channel representations of the green color shown in C, E, H and J,

respectively.

**Figure 2. *Lrig3<sup>-/-</sup>* mice have expanded mucosal area**. A. Scatter plot indicating adult *Lrig3<sup>-/-</sup>* mice have significantly longer colons, as measured from cecum to rectum, compared to wildtype mice (n=10 mice/genotype).  B. Scatter plot indicating adult *Lrig3<sup>-/-</sup>* mice have significantly more mucosal area in their colon, compared to wildtype mice (n=4, 10 images/mouse). C-D. Representative colon cross sections of wildtype and *Lrig3<sup>-/-</sup>* mice that have been stained with hematoxylin and eosin. Dashed line indicates the area measured for mucosal area. E. Scatter plot indicating adult *Lrig3<sup>-/-</sup>* mice have more nuclei per crypt compared to WT mice (n=4 mice/genotype, 10 images/mouse). F. Scatter plot indicating no significant change in proliferation (Ki67) between *Lrig3<sup>-/-</sup>* and wildtype mice (n=4 mice/genotype, 10 images/mouse, 152 crypts/genotype). G-J. Representative images of colonic tissue sections with anti-Ki67 antibody reactivity in *Lrig3<sup>-/-</sup>* (I-J) and wildtype (G-H) adult animals. Nuclei in H and J are depicted in magenta. In all plots, error bars indicate standard deviation from the mean. Significance was determined using an unpaired t-test where a significant difference between the groups is represented by an asterisk (*) when $p<0.05$. When $p<.01.$, the data have been labeled with two asterisks (**), and by (****) when $p<0.0001$. Scale bar in C-D indicates 50um. All breaks in the Y axes are shown with parallel lines. G and I are single channel representations of the green color shown in H and J, respectively.

**Figure 3. Expansion of the stem cell niche.** A-D. Representative RNA SCOPE images of colonic tissue cross sections indicating *Lgr5* transcripts (green) between wildtype (A-B) and *Lrig3<sup>-/-</sup>* (C-D) mice. E. Representative images of low, mid, and high *Lgr5+* transcript expression. F. Scatter plot indicating *Lrig3<sup>-/-</sup>* mice have significantly more *Lgr5<sup>+</sup>* mid and high cell transcript expression compared to wildtype mice (n=3 mice/genotype, 4

images/mouse). G-J. Representative images of colonic tissue sections comparing

expression of Reg4 antibody reactivity. Dotted line depicts the center of the crypt where

they were marked and quantified crypt upper half and lower half. K. Scatter plot indicating

an increase in Reg4+ cells, in the lower half of the colonic crypt, in $Lrig3^{-/-}$ mice compared

to wildtype mice (n=7 mice/genotype, 7 images/mouse). L. Scatter plot indicating no

change in Reg4+ cells in the upper portion of the colonic crypt of Lrig3$^{-/-}$ mice compared

to wildtype mice (n=7 mice/genotype, 7 images/mouse). Nuclei in B-E are depicted in

magenta. Scale bar indicates 50um. In all plots, error bars indicate standard deviation

from the mean. Significance was determined using an unpaired t-test where a significant

difference between the groups is represented by an asterisk (*) when p<0.05. When

p<.01., the data have been labeled with two asterisks (**), when p<0.0001, the data have

been labeled with four asterisks (****). A, C, G and I are single channel representations

of the green color shown in B, D, H and J, respectively.

**Figure 4. Expression of Lrig1 is expanded in $Lrig3^{-/-}$ mice.** A-D. Representative

images of colonic tissue sections comparing the expression of Lrig1 between wildtype (A-

B) and $Lrig3^{-/-}$ (C-D) mice. In A and C, Lrig1 (white) is detected at the cell membrane of

cells located in the crypt base. In B and D, Lrig1 (green) is shown in the context of all cells

in the crypt (magenta). E. Scatter plot indicating significantly more Lrig1$^{+}$ cells in the

colonic crypt of Lrig3$^{-/-}$ mice compared to wildtype (n=4 mice/genotype, 10

images/mouse). F. Western blot comparing Lrig1 antibody reactivity in wildtype and $Lrig3^{-}$

$^{/-}$ colonic tissue cell lysates (n=3). G-J. Representative images of colonic tissue sections

comparing the expression of pEgfr (I and J, green) and Egfr (G-H, green) between

wildtype and *Lrig3^-/-* mice. K. Representative western blots comparing protein expression

for Egfr, Erk1/2, and pErk1/2 in wildtype and *Lrig3^-/-* colonic tissue cell lysates (n=3).

Nuclei in G-J are depicted in magenta. Scale bars indicate 50um. Significance in scatter

plot was determined using an unpaired t- test where a significant difference between the

groups is represented by an asterisk (****) when p<0.0001. A and C are single channel

representations of the green color shown in B and D respectively.

**Supplemental Figure 1. Wildtype and Lrig3^-/- allele map, sequence, and PCR**

**screening of mice.** A-B. Schematic representation of the wildtype and *Lrig3^-/-* genes.

Disruption of *Lrig3* was achieved through the removal of exons 4-12, joining the third and

twelfth intron. B. The intervening remaining sequence (650bp) is shown. C. Confirmatory

PCR analysis of the wildtype *Lrig3* allele, using primers that are located upstream (5') and

downstream (3') of the fourth exon, and generate 1.2kb PCR product. *Lrig3^-/-* mice do not

generate a PCR product, as they lack the 3' site. D. Confirmatory PCR analysis of the null

*Lrig3* allele, using primers that are located upstream (5') of the fourth exon and

downstream (3') of the twelfth exon, generates a 650bp product in the null mice. Wildtype

mice do not generate a PCR product under standard conditions, as that region is 10kb in

length. *Lrig3* mutant heterozygous and homozygous mice are viable and fertile. PCR

primer sequences are listed in Supplemental Table 1.

**Supplemental Figure 2. Differentiated Cell marker expression in *Lrig3^-/-* and**

**wildtype colons.** A-D**.** Representative images of Vil-1 expression (green) in the

absorptive cells of the colonic epithelium in wildtype (A-B) *Lrig3^-/-* colons (C-D). B' and D'.

Enlarged images of Vil-1 expression shown in wildtype (B and B') and *Lrig3^-/-* (D and D').

E-H. Representative images of Dclk1 expression (green) in tuft cells of colonic epithelium

in wildtype (E-F) *Lrig3*[-/-] (G-H) colons. I. Scatter plot indicating no significant change in

Dclk1[+] cells in the colonic crypts of *Lrig3*[-/-] compared to wildtype mice (n=4, 10

images/mouse). J-M. representative images of ChgA expression (green) in

neuroendocrine cells of the colonic epithelium in wildtype (J-K) and *Lrig3*[-/-] (L-M) colons.

N. Scatter plot indicating no significant change in ChgA[+] cells in the colonic epithelium of

*Lrig3*[-/-] compared to wildtype mice (n=4, 10 images/mouse). For both panels, nuclei in are

depicted in magenta and the scale bar indicates 50um.

**Supplemental Table 1**

| WT and *Lrig3*[-/-] primers | |
|---|---|
| WT & *Lrig3*[-/-] 5' primer | 5' gctaaagcagccacagagtggta 3' |
| WT 3' primer | 5' ctgtgccctcaaactgtcaa 3' |
| *Lrig3*[-/-] 3' primer | 5' ttccctggactggtaggtagctc 3' |

445   **Supplemental Table 2**

| Antibody | Company | Product# | Concentration |
|---|---|---|---|
| Lrig3 | US Biological | 151911 | 1:250(IF)<br>1:300 (WB) |
| Lrig1 | R&D Systems | AF3688 | 1:500 (IF)<br>1:300 (WB) |
| Ki67(PE) | eBiosciences | SolA15 | 1:100 (IF) |
| Egfr | abcam | ab52894 | 1:500 (IF)<br>1:1000(WB) |

| pEgfr (Y1068) | abcam | 200709 | 1:400 (IF) |
|---|---|---|---|
| Erk | Bioss | BS-0022R | 1:1000 (WB) |
| pErk | Cell Signaling Technology | 4370S | 1:1000 (WB) |
| Reg4 | R&D Systems | AF1379 | 1:100 (IF) |

## References

1. **Abousoliman I**, **Reyer H**, **Oster M**, **Murani E**, **Mohamed I**, **Wimmers K**. Genome-Wide Analysis for Early Growth-Related Traits of the Locally Adapted Egyptian Barki Sheep. *Genes (Basel)* 12, 2021. doi: 10.3390/genes12081243.

2. **Abraira VE**, **del Rio T**, **Tucker AF**, **Slonimsky J**, **Keirnes HL**, **Goodrich L V**. Cross-repressive interactions between Lrig3 and Netrin1 shape the architecture of the inner ear. *Development* 135: 4091–4099, 2008. doi: 10.1242/dev.029330.

3. **Abraira VE**, **Satoh T**, **Fekete DM**, **Goodrich L V.** Vertebrate Lrig3-ErbB interactions occur in vitrobut are unlikely to play a role in Lrig3-dependent inner ear morphogenesis. *PLoS One* 5, 2010. doi: 10.1371/journal.pone.0008981.

4. **Barker N**, **van Es JH**, **Kuipers J**, **Kujala P**, **van den Born M**, **Cozijnsen M**, **Haegebarth A**, **Korving J**, **Begthel H**, **Peters PJ**, **Clevers H**. Identification of stem cells in small intestine and colon by marker gene Lgr5 [Online]. *Nature* 449: 1003, 2007. http://dx.doi.org/10.1038/nature06196.

5. **Cai MJ**, **Xie RF**, **Han L**, **Chen RD**, **Wang BF**, **Ye F**, **Guo DS**, **Lei T**. Effect of RNAi-mediated LRIG3 gene silencing on proliferation of glioma GL15 cells and expression of PCNA and Ki-67. *Chin J Cancer* 28: 1–4, 2009.

6. **Chen Y**, **Wang Q**, **Wang M**, **Li M**. Overexpressed LRIG3 gene ameliorates prostate cancer through suppression of cell invasion and migration. *Int J Biol Macromol* 124: 1–9, 2019. doi: https://doi.org/10.1016/j.ijbiomac.2018.11.028.

7. **De Vincenti AP**, **Alsina FC**, **Ferrero Restelli F**, **Hedman H**, **Ledda F**, **Paratcha G**. Lrig1 and Lrig3 cooperate to control Ret receptor signaling, sensory axonal growth and epidermal innervation. *Development* 148, 2021. doi: 10.1242/dev.197020.

8. **del Rio T**, **Nishitani AM**, **Yu W-M**, **Goodrich L V**. In Vivo Analysis of Lrig Genes Reveals Redundant and Independent Functions in the Inner Ear [Online]. *PLOS Genet* 9: e1003824, 2013. https://doi.org/10.1371/journal.pgen.1003824.

9. **Dessimoz J**, **Opoka R**, **Kordich JJ**, **Grapin-Botton A**, **Wells JM**. FGF signaling is necessary for establishing gut tube domains alongthe anterior–posterior axis in vivo. *Mech Dev* 123: 42–55, 2006. doi: https://doi.org/10.1016/j.mod.2005.10.001.

10. **Gehart H**, **Clevers H**. Tales from the crypt: new insights into intestinal stem cells.

478  *Nat Rev Gastroenterol Hepatol* 16: 19–34, 2019. doi: 10.1038/s41575-018-0081-
479  y.

11. **Hellström M**, **Ericsson M**, **Johansson B**, **Faraz M**, **Anderson F**, **Henriksson R**, **Nilsson SK**, **Hedman H**. Cardiac hypertrophy and decreased high-density lipoprotein cholesterol in Lrig3-deficient mice [Online]. *Am J Physiol - Regul Integr Comp Physiol* 310: R1045, 2016. http://ajpregu.physiology.org/content/310/11/R1045.abstract.

12. **Hu X**, **Zhou K**, **Cao S**, **Zhu H**, **Xie K**. Circ_lrig3 contributes to the progression of hepatocellular carcinoma by elevating rnf38 via sponging mir-449a. *Gen Physiol Biophys* 40, 2021. doi: 10.4149/gpb_2020044.

13. **Kwon O**, **Han T-S**, **Son M-Y**. Intestinal Morphogenesis in Development, Regeneration, and Disease: The Potential Utility of Intestinal Organoids for Studying Compartmentalization of the Crypt-Villus Structure. *Front cell Dev Biol* 8: 593969, 2020. doi: 10.3389/fcell.2020.593969.

14. **Liu P**, **Jenkins NA**, **Copeland NG**. A highly efficient recombineering-based method for generating conditional knockout  mutations. *Genome Res* 13: 476–484, 2003. doi: 10.1101/gr.749203.

15. **Metodiev S**, **Thekkoot DM**, **Young JM**, **Onteru S**, **Rothschild MF**, **Dekkers JCM**. A whole-genome association study for litter size and litter weight traits in pigs. *Livest Sci* 211, 2018. doi: 10.1016/j.livsci.2018.03.004.

16. **Osaki LH**, **Gama P**. MAPKs and Signal Transduction in the Control of Gastrointestinal Epithelial Cell Proliferation and Differentiation. *Int J Mol Sci* 14: 10143–10161, 2013. doi: 10.3390/ijms140510143.

17. **Peng C**, **Chen H**, **Li Y**, **Yang H**, **Qin P**, **Ma B**, **Duan Q**, **Wang B**, **Mao F**, **Guo D**. LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma. *Front Oncol* 11: 54, 2021. doi: 10.3389/fonc.2021.621154.

18. **Powell AE**, **Wang Y**, **Li Y**, **Poulin EJ**, **Means AL**, **Washington MK**, **Higginbotham JN**, **Juchheim A**, **Prasad N**, **Levy SE**, **Guo Y**, **Shyr Y**, **Aronow BJ**, **Haigis KM**, **Franklin JL**, **Coffey RJ**. The pan-ErbB negative regulator, Lrig1, is an intestinal stem cell marker that functions as a tumor suppressor. *Cell* 149: 146–158, 2012. doi: 10.1016/j.cell.2012.02.042.

19. **Qiu Y**, **Han Q**, **Lu H**, **Shi C**. miR-196a targeting LRIG3 promotes the proliferation and migration of cervical cancer cells. *Cell Mol Biol* 66, 2020. doi: 10.14715/cmb/2020.66.7.27.

20. **Sasaki N**, **Sachs N**, **Wiebrands K**, **Ellenbroek SIJ**, **Fumagalli A**, **Lyubimova A**, **Begthel H**, **Van Born M Den**, **Van Es JH**, **Karthaus WR**, **Li VSW**, **López-Iglesias C**, **Peters PJ**, **Van Rheenen J**, **Van Oudenaarden A**, **Clevers H**. Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. *Proc Natl Acad Sci U S A* 113: E5399–E5407, 2016. doi: 10.1073/pnas.1607327113.

518    21.    **Schlieve CR**, **Mojica SG**, **Holoyda KA**, **Hou X**, **Fowler KL**, **Grikscheit TC**.
519            Vascular Endothelial Growth Factor (VEGF) Bioavailability Regulates
520            Angiogenesis and Intestinal Stem and Progenitor Cell Proliferation during
521            Postnatal Small Intestinal Development [Online]. *PLoS One* 11: e0151396, 2016.
522            https://doi.org/10.1371/journal.pone.0151396.

523    22.    **Simion C**, **Prieto MEC**, **Sweeney C**. The LRIG family – enigmatic regulators of
524            growth factor receptor signaling. *Endocr Relat Cancer* 21: R431–R443, 2014. doi:
525            10.1530/ERC-14-0179.

526    23.    **Sun H**, **Zhai J**, **Zhang L**, **Chen Y**. CircRNA LRIG3 knockdown inhibits
527            hepatocellular carcinoma progression by regulating miR-223-3p and MAPK/ERK
528            pathway. .

529    24.    **Sun S**, **Gao J**, **Zhou S**, **Li Y**, **Wang Y**, **Jin L**, **Li J**, **Liu B**, **Zhang B**, **Han S**, **Ding**
530            **H**, **Li X**. A novel circular RNA circ-LRIG3 facilitates the malignant progression of
531            hepatocellular carcinoma by modulating the EZH2/STAT3 signaling. *J Exp Clin*
532            *Cancer Res* 39: 252, 2020. doi: 10.1186/s13046-020-01779-5.

533    25.    **Wang Y**, **Shi C**, **Lu Y**, **Poulin EJ**, **Franklin JL**, **Coffey RJ**. Loss of Lrig1 leads to
534            expansion of Brunner glands followed by duodenal adenomas with gastric
535            metaplasia. *Am J Pathol* 185: 1123–34, 2015. doi: 10.1016/j.ajpath.2014.12.014.

536    26.    **Wong VWY**, **Stange DE**, **Page ME**, **Buczacki S**, **Wabik A**, **Itami S**, **van de**
537            **Wetering M**, **Poulsom R**, **Wright NA**, **Trotter MWB**, **Watt FM**, **Winton DJ**,
538            **Clevers H**, **Jensen KB**. Lrig1 controls intestinal stem cell homeostasis by
539            negative regulation of ErbB signalling. *Nat Cell Biol* 14: 401–408, 2012. doi:
540            10.1038/ncb2464.

541    27.    **Yui S**, **Azzolin L**, **Maimets M**, **Pedersen MT**, **Fordham RP**, **Hansen SL**, **Larsen**
542            **HL**, **Guiu J**, **Alves MRP**, **Rundsten CF**, **Johansen J V**, **Li Y**, **Madsen CD**,
543            **Nakamura T**, **Watanabe M**, **Nielsen OH**, **Schweiger PJ**, **Piccolo S**, **Jensen KB**.
544            YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM
545            Remodeling to Tissue Regeneration. *Cell Stem Cell* 22: 35-49.e7, 2018. doi:
546            10.1016/j.stem.2017.11.001.

547    28.    **Zeng K**, **Chen X**, **Xu M**, **Liu X**, **Li C**, **Xu X**, **Pan B**, **Qin J**, **He B**, **Pan Y**, **Huiling**
548            **S**, **Xu T**, **Wang S**. LRIG3 represses cell motility by inhibiting slug via inactivating
549            ERK signaling in human colorectal cancer. *IUBMB Life* : 1–11, 2020. doi:
550            10.1002/iub.2262.

551    29.    **Zeng K**, **Chen X**, **Xu M**, **Liu X**, **Li C**, **Xu X**, **Pan B**, **Qin J**, **He B**, **Pan Y**, **Huiling**
552            **S**, **Xu T**, **Wang S**. LRIG3 represses cell motility by inhibiting slug via inactivating
553            ERK signaling in human colorectal cancer. *IUBMB Life* : 1–11, 2020. doi:
554            10.1002/iub.2262.

555    30.    **Zhao H**, **Tanegashima K**, **Ro H**, **Dawid IB**. Lrig3 regulates neural crest formation
556            in Xenopus by modulating Fgf and Wnt  signaling pathways. *Development* 135:
557            1283–1293, 2008. doi: 10.1242/dev.015073.

558    31.    **Zhou H**, **Cao J**, **Yang F**, **Fan D**, **Li H**, **Fan T**, **Sun P**.  Member Domain 3 (LRIG3)

559      Activates Hypoxia-Inducible Factor-1 α /Vascular Endothelial Growth Factor (HIF-
560      1 α /VEGF) Pathway to Inhibit the Growth of Bone Marrow Mesenchymal Stem
561      Cells in Glioma . *J Biomater Tissue Eng* 11, 2021. doi: 10.1166/jbt.2021.2629.

562   32.   Genepaint [Online]. [date unknown]. https://gp3.mpg.de.

# Figure 1

Figure 2

# Figure 3

**A** *Lgr5*

**B** *Lgr5* DAPI

**C** *Lgr5*

**D** *Lgr5* DAPI

Wildtype

*Lrig3⁻/⁻*

**E**

low *Lgr5+* expression

mid *Lgr5+* expression

high *Lgr5+* expression

**G** Reg4

**H** Reg4 DAPI

**I** Reg4

**J** Reg4 DAPI

Wildtype

*Lrig3⁻/⁻*

**F**

Lgr5+ cells/crypt image

ns    **    ****

Wildtype    Lrig3⁻/⁻    Wildtype    Lrig3⁻/⁻    Wildtype    Lrig3⁻/⁻

low    mid    high

*Lgr5* expression

**K**

Reg4+ cells (lower)/crypt

****

Wildtype    Lrig3⁻/⁻

**L**

Reg4+ cells (upper)/crypt

ns

Wildtype    Lrig3⁻/⁻

**E** Lrig1+ cells/crypt

Wildtype    *Lrig3⁻/⁻*

**F**

| | Wildtype | *Lrig3⁻/⁻* |
|---|---|---|
| Lrig1 | | |
| β-Tubulin | | |

**K**

| | Wildtype | *Lrig3⁻/⁻* |
|---|---|---|
| Egfr | | |
| Erk1/2 | | |
| pErk1/2 | | |
| β-tubulin | | |